SLC5A2 and chronic kidney disease: Established treatments include SGLT2 inhibitors, GLP-1RAs, and mineralocorticoid receptor antagonists like finerenone, which have demonstrated benefits in reducing cardiovascular events, slowing CKD progression, and improving metabolic parameters.